MedTrace Logo

A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301

NCT06363760 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 54

Last updated 2025-04-02

No results posted yet for this study

Summary

The purpose of this study is to evaluate the long-term safety and efficacy of EDIT-301 in participants with severe sickle cell disease (SCD) or transfusion-dependent β-thalassemia (TDT) who have received EDIT-301.

Conditions

Interventions

OTHER

Safety and efficacy assessments

Assessed throughout the duration of the study.

Sponsors & Collaborators

  • Editas Medicine, Inc.

    lead INDUSTRY

Eligibility

Min Age
12 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-17
Primary Completion
2040-08-31
Completion
2040-08-31
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06363760 on ClinicalTrials.gov